System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device

• US 8,090,435 B2
• Filed: 01/27/2009
• Issued: 01/03/2012
• Est. Priority Date: 01/25/2005
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gill, Jong, Boileau, Peter, Bharmi, Rupinder, Min, Xiaoyi, Florio, Joseph J., Benser, Michael E., Bornzin, Gene A.
• Primary Examiner(s): KAHELIN, MICHAEL WILLIAM
• Application Number:
  US12/360,826
• Publication Number:
  US 20090177105A1
• Time in Patent Office: 1,071 Days
• Field of Search: 600/517
• US Class Current: 600/517
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/358 Detecting ST segments
• CPC Class Codes: A61B 5/364 Detecting abnormal ECG interval, e.g. extrasystoles, ectopic heartbeats
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting
• CPC Class Codes: A61N 1/3962 in combination with another heart therapy
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

Techniques are described for detecting ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. Ischemia is detected based on a shortening of the interval between the QRS complex and the end of a T-wave (QTmax), alone or in combination with a change in ST segment elevation. Alternatively, ischemia is detected based on a change in ST segment elevation combined with minimal change in the interval between the QRS complex and the end of the T-wave (QTend). Hypoglycemia is detected based on a change in ST segment elevation along with a lengthening of either QTmax or QTend. Hyperglycemia is detected based on a change in ST segment elevation along with minimal change in QTmax and in QTend. By exploiting QTmax and QTend in combination with ST segment elevation, changes in ST segment elevation caused by hypo/hyperglycemia can be properly distinguished from changes caused by ischemia.

Claims

1. A method for use with an implantable medical device for detecting hyperglycemia in a patient in which the device is implanted, said method comprising:

tracking repolarization peak-based intervals representative of intervals between depolarization events and peaks of corresponding repolarization events within electrical cardiac signals;

tracking of elevations of segments of the cardiac signals between ends of depolarization events and beginnings of corresponding repolarization events with respect to a corresponding baseline elevation; and

detecting an episode of hyperglycemia based on a change in the the elevations of the segments in combination with a lack of change in the repolarization peak-based intervals.

2. The method of claim 1 wherein the repolarization peak-based intervals are representative of intervals between QRS complexes and peaks of corresponding T-waves (QTmax intervals).

3. The method of claim 1 wherein the segment elevations are representative of the elevations of segments of cardiac signals between QRS-complexes and corresponding T-waves (ST segments).

4. The method of claim 1 further including tracking patient heart rate and wherein the repolarization-peak based intervals are normalized based on heart rate.

5. The method of claim 1 wherein detecting an episode of hyperglycemia is based on significant changes in the segment elevations of a plurality of heartbeats compared to a baseline elevation combined with a lack of significant change in repolarization-based intervals of a plurality of heartbeats compared to baseline intervals.

6. The method of claim 1 further including recording diagnostic information representative of the intervals and segment elevations.

7. The method of claim 1 further including controlling therapy in response to the detection of an episode of hyperglycemia.

8. The method of claim 7 wherein an implantable insulin pump is provided and wherein controlling therapy in response to the detection of an episode of hyperglycemia includes controlling insulin delivery to the patient using the insulin pump.

9. The method of claim 1 further including generating a warning signal in response to detection of an episode of hyperglycemia.

10. The method of claim 9 wherein an implantable warning device is provided and wherein generating a warning signal includes the step of delivering a perceptible warning signal to the patient via the implantable warning device.

11. The method of claim 10 for use with an external warning device and wherein the step of generating a warning signal includes the step of transmission control signals to the external warning device for controlling the external device to generate warning signals for warning the patient.

12. An implantable medical device for detecting hyperglycemia in a patient in which the device is implanted, said device comprising:

a timing unit operative to track repolarization peak-based intervals representative of intervals between depolarization events and peaks of corresponding repolarization events within electrical cardiac signals, and to track of elevations of segments of the cardiac signals between ends of depolarization events and beginnings of corresponding repolarization events with respect to a corresponding baseline elevation; and

a hyperglycemia detection unit operative to detect an episode of hyperglycemia based on changes or lack of changes in the elevations of the segments and the repolarization peak-based intervals.

13. The device of claim 12 wherein the hyperglycemia detection unit detects an episode of hyperglycemia when there is a change in the elevations of the segments in combination with a lack of change in the repolarization peak-based intervals.

14. The device of claim 12 wherein the repolarization peak-based intervals tracked by the timing unit are representative of intervals between QRS complexes and peaks of corresponding T-waves (QTmax intervals).

15. The device of claim 12 wherein the segment elevations tracked by the timing unit are representative of the elevations of segments of cardiac signals between QRS-complexes and corresponding T-waves (ST segments).

16. The device of claim 12 wherein the hyperglycemia detection unit is operative to detect an episode of hyperglycemia based on significant changes in the segment elevations of a plurality of heartbeats compared to a baseline elevation combined with a lack of significant change in repolarization-based intervals of a plurality of heartbeats compared to baseline intervals.